Navigation Links
Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
Date:6/15/2010

JERUSALEM, June 15, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of alternative drug delivery systems, announced today that results of two of its clinical trials will be presented by Chief Scientific Officer Dr. Miriam Kidron, at the forthcoming 70th Annual Scientific Sessions of the American Diabetes Association, to be held in Orlando, Florida. The first abstract, entitled "Oral Insulin: Type I Diabetes (T1DM) Patient Response Upon Preprandial Administration" examines exposure of Type 1 diabetes patients to Oramed's oral insulin. The second abstract, entitled "A Single-Blind, Two-period Study to Assess the Safety and Pharmacodynamics of an Orally Delivered GLP-1 Analog (Exenatide) in Healthy Subjects" details a first-in-human study with Oramed's oral GLP-1 Analog.

The posters will be presented on June 28, 2010 at 12:00 PM - 2:00 PM in the Poster Hall. The posters will also be printed in the Scientific Sessions Abstract book which is the June 2010 supplement for the Journal Diabetes. The posters will be displayed throughout the conference for viewing in the Poster Hall.

The poster entitled "Oral Insulin: Type I Diabetes (T1DM) Patient Response Upon Preprandial Administration" will be featured in a guided tour in the Poster Hall. The tour title is "Innovations in Novel Insulin Preparations" and is scheduled for Monday June 28 at

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
5. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
9. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
10. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
11. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ... new report "Cytogenetics - Technologies, Markets and ... report deals with cytogenetics in a broader sense ... the chromosome structure and identify abnormalities related to ... is also referred to as molecular cytogenetics. The ...
(Date:5/29/2015)... MILWAUKEE, WISCONSIN (PRWEB) May 29, 2015 ... oncolytic virus talimogene laherparepvec and its ability to reduce ... the treatment have been published in the Journal of ... 436 patients with stages IIIB, IIIC and IV melanoma, ... goal of the study was to evaluate the safety ...
(Date:5/29/2015)... Fort Worth, Texas (PRWEB) May 29, 2015 ... can grow. This is for a good reason--if used in ... work wonders for the offering of a business product or ... in which translation can have a positive effect on a ... product or service that anyone in the world can use, ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Technologies, Markets, and Companies" to their ... This report deals with therapeutic ... at improving patient care by monitoring drug ...
Breaking Biology Technology:Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Three Ways Translation Can Help Businesses Grow 2Global Therapeutic Drug Monitoring Market 2015-2024 2
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... Vista Partners announced today that,it has initiated coverage on ... of Research of Vista Partners stated, "Synvista is one ... across. The,company is conducting four Phase 2 trials in ... a $100M market, could begin to,produce revenues as early ...
... Phase 1c Study Demonstrates Dose-dependent Activity of Antidote ... Biosciences today announced,the Journal of Thrombosis and Haemostasis, ... and Haemostasis, has published the,Phase 1c clinical results ... two-component system comprised of an aptamer-based anticoagulant,RB006, and ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI) 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 3Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 4
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/10/2015)... -- Fingerprint Cards (FPC) has received an order ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... in China . The order value of ... + 1 000 MSEK for 2015.   Jörgen Lantto, ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... led to an epidemic of obesity and type-2 diabetes in ... University that are due to be published in the 5 ... of Science and also in the PNAS early online edition ... expands the known taxonomic breadth of metabolic disease and suggests ...
... basis for eventual treatment, neurology researchers have shown that ... that helps keep brain activity in balance. The resulting ... underlying reason for seizures and memory defects experienced by ... , "A traumatic brain injury occurs to someone in ...
... have discovered that autoimmunity can be triggered in the thymus, ... fail to recognize just one of the body's thousands of ... that autoimmunity can start in this cradle of the immune ... emerge, such as the pancreas in the case of type ...
Cached Biology News:Dragonfly's metabolic disease provides clues about human obesity 2Dragonfly's metabolic disease provides clues about human obesity 3Dragonfly's metabolic disease provides clues about human obesity 4Dragonfly's metabolic disease provides clues about human obesity 5How brain injury leads to seizures, memory problems 2Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
... DMEM and harvested at the log phase of ... in their native forms, cells were fixed in ... 12-well (5 mm) adhesive coated slide, with each ... and to minimize background staining. Each well ...
... be induced prior to DNA purification increasing ... of single-copy BACs with the high yields ... The kits provide the linearized vector and ... system) necessary to create a 10X human ...
... induced prior to DNA purification increasing DNA ... single-copy BACs with the high yields associated ... kits provide the linearized vector and associated ... necessary to create a 10X human BAC ...
ID clarifier: Without ethidium bromide...
Biology Products: